Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer
The diagnostic performance of CA19-9 for early-stage PC patients could be improved by combining sPCSK9 with CA19-9. Moreover, the higher sPCSK9 group has a significantly shorter overall survival rate.
Authors
- Ying Xu (ORCID: https://orcid.org/0000-0001-9057-227X)
- Yongfeng Xu (ORCID: https://orcid.org/0000-0002-5820-6429)
- Qunli Xiong (ORCID: https://orcid.org/0000-0001-8319-2834)
- Yang Yang (ORCID: https://orcid.org/0000-0002-8392-2830)
- Qing Zhu (ORCID: https://orcid.org/0000-0003-2182-5709)
- Zhiwei Zhang (ORCID: https://orcid.org/0000-0001-9648-9119)
Institutions
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2024-09-10
- DOI
- https://doi.org/10.7717/peerj.18018
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Sichuan University
- West China Hospital, Sichuan University